文献速递肾小球疾病遗传性与小管间质肾病

mRNA测序识别X连锁Alport综合征中的异常剪接

mRNA Sequencing to Identify Aberrant Splicing in X-linked Alport Syndrome.
PubMed 文献 · Kidney Int Rep · 2026-04-22

该研究对11例常规基因检测未发现致病变异的临床疑似X连锁Alport综合征患者进行mRNA分析,在2例意义不明变异中确认致病性,在7例中发现新的深内含子致病变异,其中5例剪接异常完全、4例部分,部分剪接异常者肾脏病较轻。

要点

  • mRNA分析可确认内含子区意义不明变异的致病性。
  • mRNA分析可指导发现深内含子致病变异。
  • 部分剪接异常者肾脏病表型较轻。

核心结论

  • mRNA分析有助于确认变异致病性或发现内含子变异,从而建立XLAS遗传诊断。

研究设计与样本

  • 研究纳入11例具有XLAS临床特征且常规分析未发现致病变异的患者,其中2例检出内含子剪接区意义不明变异。
  • 采用成纤维细胞或尿源性足细胞谱系细胞进行mRNA分析。

主要发现

  • 2例意义不明变异经mRNA分析确认致病性。
  • 9例通过mRNA分析评估异常剪接并指导基因组DNA测序,其中7例发现新的深内含子致病变异。
  • 剪接异常完全者5例,部分者4例,部分剪接异常组肾脏病较轻。

临床怎么用

  • 对临床疑似Alport综合征但常规基因检测未发现致病变异者,可考虑mRNA分析辅助诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: X-linked Alport syndrome (XLAS) is a well-known monogenetic kidney disease caused by pathogenic variants in the COL4A5 gene. Routine analysis of exons and direct flanking regions fails to identify a pathogenic variant in 10% to 20% of patients with XLAS. METHODS: We evaluated 11 selected patients with clinical features of XLAS, in whom routine analysis failed to identify a pathogenic variant. In 2 patients a variant of unknown significance was detected in the intronic splice site regions. We used mRNA analysis from fibroblasts or urine-derived podocyte-lineage cells to establish a genetic diagnosis. RESULTS: In 2 patients with a variant of unknown significance (VUS), mRNA analysis confirmed the pathogenicity. In 9 patients, mRNA analysis was used to evaluate aberrant splicing and guide genomic DNA sequencing. In 7 patients a novel pathogenic deep-intronic variant was found. Overall, aberrant splicing was complete in 5 patients and partial in 4, whereas kidney disease was less severe in the latter group. CONCLUSION: This report highlights the importance of mRNA analysis to confirm pathogenicity or facilitate the search for intronic variants to establish a genetic diagnosis in XLAS. This analysis can serve as a diagnostic tool in patients suspected for Alport syndrome (AS) when routine genetic analysis fails to identify a pathogenic variant.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Rao D, van den Berge BT, Vulto-van Silfhout AT, et al. mRNA Sequencing to Identify Aberrant Splicing in X-linked Alport Syndrome. Kidney Int Rep. 2026. PMID: 42254845. doi:10.1016/j.ekir.2026.106553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。